Thrombologic initiates it second clinical trial, an exploratory phase IIa in patients with severe community acquired pneumonia. The trial will be run in collaboration with professor Anders Perner of Copenhagen University hospital, it will run in Denmark and Finland. The trials primary end-point is safety and the secondary end-points efficacy. Data is expected to be available 3Q 2013.